Oncology Business Management | Specialty

Determining Progression in Renal Cell Carcinoma

July 1st 2013

AXIS Trial: Second-Line Axitinib Versus Sorafenib

July 1st 2013

Frontline Sunitinib Compared to Everolimus in mRCC

July 1st 2013

Utilizing Frontline Bevacizumab in mRCC

July 1st 2013

AGILE Trial: Frontline Axitinib Versus Sorafenib in mRCC

July 1st 2013

PISCES Trial and Patient Treatment Preference in mRCC

July 1st 2013

COMPARZ Trial and Alternate Sunitinib Dosing Schedule

July 1st 2013

Introduction and Review of the COMPARZ Trial in RCC

July 1st 2013

Dr. Schilsky on the Impact of Sequestration on the FDA

June 27th 2013

Richard L. Schilsky, MD, from the University of Chicago Comprehensive Cancer Center, discusses sequestration and the effect on the FDA.

Clinical Next-Generation Sequencing to Guide Cancer Treatment Decisions

June 26th 2013

In the past year, clinical laboratories have begun determining the tumor mutational status of multiple genes simultaneously using next-generation sequencing platforms.

Dr. Tendler on Breakthrough Designation for Ibrutinib

June 26th 2013

Craig L. Tendler, MD, Vice President, Late Development and Global Medical Affairs for Oncology, Janssen Oncology, discusses the importance of ibrutinib's Breakthrough Therapy Designation.

Ellen Matloff on the Supreme Court Gene Patenting Decision

June 25th 2013

Ellen T. Matloff, MS, CGC, from the Yale School of Medicine/Yale Cancer Center, describes the impact of the US Supreme Court decision to restrict the patenting of segments of DNA in isolation.

Lessons From the Other Side of the Bed: Physician Perspectives as a Cancer Patient

June 20th 2013

Oncologist Jennifer Kelly, MD, PhD, shares her personal experiences as a stomach cancer patient, recognizes the barriers between cancer care providers and patients, and suggests ways of improving these interactions.

Dr. Hershman on the Use of Compendia-Approved Drugs

June 17th 2013

Dawn L. Hershman, MD, MS, discusses improving care and the use of compendia-approved oncology drugs.

Clinical Pathways: An Evolutionary Approach to Cancer Care

June 14th 2013

Clinical pathway programs are evolving as a primary means by which payers intend to control drug utilization in cancer treatment.

CRPC Challenge: Sequencing Chemotherapy With New Agents

June 12th 2013

Challenges remain regarding the mechanisms of docetaxel resistance, whether combination studies continue to make sense, and how the sequencing of docetaxel may impact toxicity and efficacy.

FDA Rejects Tivozanib for Kidney Cancer, Recommends Additional Clinical Study

June 10th 2013

The FDA has rejected a new drug application for tivozanib for the treatment of advanced renal cell carcinoma, recommending an additional clinical trial to address concerns over existing clinical data.

Drug Shortages Adversely Affect Treatment Decisions

June 3rd 2013

Shortages of cancer drugs caused many oncologists and hematologists to choose suboptimal treatment plans for their patients last year, and government efforts have done little to boost the availability of the hard-to-find medications.

Dr. Pazdur on Breakthrough Designation Requirements

May 31st 2013

Richard Pazdur, MD, from the FDA's Center for Drug Evaluation and Research, emphasizes the importance of adequate data supporting proposals to the FDA for breakthrough therapy designations.

Dabrafenib and Trametinib Both Approved for Advanced Melanoma

May 29th 2013

The FDA approved both dabrafenib and trametinib for the treatment of patients with metastatic or unresectable melanoma, as well as a companion diagnostic to properly identify the patients exhibiting the mutations that are targeted by these agents.